The novel coronavirus disease (COVID-19) pandemic has created a shift in the conduct of healthcare, particularly in the use of digital technology in enabling virtual experiences for both physicians and patients, as suggested by experts in the recently concluded 2020 Virtual Forum of the Asia Pacific Medical Technology Association (APACMed 2020).
From a typical brick-and-mortar environment to the application of digital and data technologies to engage patients at a safe distance, the pandemic has facilitated a shift in the delivery of healthcare.
The coronavirus disease (COVID-19) pandemic appears to have quickened the acceptance of prescription digital therapeutics (PDT), or software that helps treat human disease, by clinicians and patients, particularly those suffering from mental health conditions, according to experts from one of the sessions at the 2020 Virtual Forum of the Asia Pacific Medical Technology Association (APACMed 2020).
Digital technology is key in improving access to healthcare. This was the key message in one of the breakout sessions during the recently concluded 2020 Virtual Forum of the Asia Pacific Medical Technology Association (APACMed 2020). Especially under lockdowns due to the coronavirus pandemic, digital health allows providers to continuously deliver services to their patients.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.